Elutia sells BioEnvelope business to Boston Scientific for $88 million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million
September 9, 2025 8:30 AM EDT- Transaction affirms the strength of Elutias proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction -
- Company to provide update at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10 at 9:30 a.m. ET -
GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (Elutia or the Company), a pioneer in drug-eluting biomatrix technologies, today announced it has entered into a definitive agreement to sell its EluPro and CanGaroo® bioenvelopes, designed to protect patients receiving implantable... More
